Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Necitumumab: Phase III data

The open-label, international Phase III SQUIRE trial in 1,093 stage IV squamous NSCLC patients showed that first-line treatment with 800 mg IV nectiumumab on days 1 and 8 of a 21-day cycle

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE